• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

持续低效透析治疗对危重症患者伊曲康唑血药浓度的影响。

Influence of Sustained Low-Efficiency Dialysis Treatment on Isavuconazole Plasma Levels in Critically Ill Patients.

机构信息

Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar der Technischen Universität Munich, Munich, Germany

Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar der Technischen Universität Munich, Munich, Germany.

出版信息

Antimicrob Agents Chemother. 2019 Oct 22;63(11). doi: 10.1128/AAC.01162-19. Print 2019 Nov.

DOI:10.1128/AAC.01162-19
PMID:31427296
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6811396/
Abstract

Isavuconazole plasma concentrations were measured before and after sustained low-efficiency dialysis (SLED) treatment in 22 critically ill adult patients with probable invasive aspergillosis and underlying hematological malignancies. Isavuconazole levels were significantly lower after SLED treatment (5.73 versus 3.36 μg/ml; < 0.001). However, even after SLED treatment, isavuconazole concentrations exceeded the MICs for several relevant species.

摘要

在 22 例患有疑似侵袭性曲霉菌病和潜在血液恶性肿瘤的重症成年患者中，在持续低效透析（SLED）治疗前后测量了伊曲康唑的血浆浓度。SLED 治疗后伊曲康唑水平显著降低（5.73 对 3.36μg/ml；<0.001）。然而，即使在 SLED 治疗后，伊曲康唑浓度仍超过了几种相关物种的 MIC 值。

相似文献

1
Influence of Sustained Low-Efficiency Dialysis Treatment on Isavuconazole Plasma Levels in Critically Ill Patients.持续低效透析治疗对危重症患者伊曲康唑血药浓度的影响。
Antimicrob Agents Chemother. 2019 Oct 22;63(11). doi: 10.1128/AAC.01162-19. Print 2019 Nov.
2
Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials.在 3 期 SECURE 和 VITAL 试验中，用伊曲康唑或伏立康唑治疗侵袭性曲霉病患者的 MIC 值结果。
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01634-18. Print 2019 Jan.
3
Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi.来自1期和3期（SECURE）试验的成人艾沙康唑群体药代动力学以及曲霉和其他丝状真菌所致侵袭性感染患者的目标达成情况
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5483-91. doi: 10.1128/AAC.02819-15. Print 2016 Sep.
4
Isavuconazole: Case Report and Pharmacokinetic Considerations.伊曲康唑：病例报告及药代动力学考虑。
Chemotherapy. 2018;63(5):253-256. doi: 10.1159/000494329. Epub 2018 Nov 20.
5
Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method.EUCAST 方法测定曲霉属和念珠菌属物种的伊曲康唑敏感性。
Antimicrob Agents Chemother. 2013 Nov;57(11):5426-31. doi: 10.1128/AAC.01111-13. Epub 2013 Aug 19.
6
Direct in vitro comparison of the prodrug isavuconazonium sulfate with the isavuconazole active compound against Aspergillus spp. and 2 rare moulds.前体药物硫酸艾沙康唑与艾沙康唑活性化合物针对曲霉菌属及两种罕见霉菌的直接体外比较
Diagn Microbiol Infect Dis. 2018 Sep;92(1):43-45. doi: 10.1016/j.diagmicrobio.2018.04.005. Epub 2018 Apr 13.
7
Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients.静脉注射伊曲康唑在实体器官移植受者中的药代动力学。
Antimicrob Agents Chemother. 2018 Nov 26;62(12). doi: 10.1128/AAC.01643-18. Print 2018 Dec.
8
Lessons from isavuconazole therapeutic drug monitoring at a United Kingdom Reference Center.英国参考中心伊曲康唑治疗药物监测的经验教训。
Med Mycol. 2020 Oct 1;58(7):996-999. doi: 10.1093/mmy/myaa022.
9
Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases.在侵袭性霉菌病患者的 3 期 SECURE 试验中，伊沙康唑的血药浓度变异性和暴露-反应关系。
J Antimicrob Chemother. 2019 Mar 1;74(3):761-767. doi: 10.1093/jac/dky463.
10
Isavuconazole therapeutic drug monitoring in critically ill ICU patients: A monocentric retrospective analysis.重症监护病房危重症患者伊曲康唑治疗药物监测：一项单中心回顾性分析。
Mycoses. 2022 Jul;65(7):747-752. doi: 10.1111/myc.13469. Epub 2022 May 31.

引用本文的文献

1
Low isavuconazole trough levels in critically ill patients with and without extracorporeal membrane oxygenation.伴有和不伴有体外膜肺氧合的危重症患者中艾沙康唑谷浓度较低。
Antimicrob Agents Chemother. 2025 Sep 3;69(9):e0057725. doi: 10.1128/aac.00577-25. Epub 2025 Jul 23.
2
[S1 guideline: diagnosis and treatment of invasive pulmonary aspergillosis in critically ill/intensive care patients].[S1 指南：危重症/重症监护患者侵袭性肺曲霉病的诊断与治疗]
Med Klin Intensivmed Notfmed. 2025 May;120(4):271-289. doi: 10.1007/s00063-025-01265-w. Epub 2025 Mar 21.
3
Population Pharmacokinetics of Isavuconazole in Critical Care Patients with COVID-19-Associated Pulmonary Aspergillosis and Monte Carlo Simulations of High Off-Label Doses.艾沙康唑在新冠病毒相关肺曲霉病重症监护患者中的群体药代动力学及高超说明书剂量的蒙特卡洛模拟
J Fungi (Basel). 2023 Feb 6;9(2):211. doi: 10.3390/jof9020211.
4
Isavuconazole Treatment in a Mixed Patient Cohort with Invasive Fungal Infections: Outcome, Tolerability and Clinical Implications of Isavuconazole Plasma Concentrations.在患有侵袭性真菌感染的混合患者队列中使用艾沙康唑治疗：艾沙康唑血药浓度的疗效、耐受性及临床意义
J Fungi (Basel). 2020 Jun 22;6(2):90. doi: 10.3390/jof6020090.
5
Reply to Baud and Houzé, "Should and Studies on Antimicrobial Agents during Continuous Renal Replacement Therapy Comply with General Principles of Pharmacokinetics?".对博德和胡泽的回复：“连续性肾脏替代治疗期间抗菌药物的研究是否应遵循药代动力学的一般原则？”
Antimicrob Agents Chemother. 2020 May 21;64(6). doi: 10.1128/AAC.00401-20.

本文引用的文献

1
Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials.真实世界实践中的伊曲康唑浓度：与临床试验结果的一致性。
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.00585-18. Print 2018 Jul.
2
Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity.伊曲康唑：一种新型广谱唑类药物。第 2 部分：药代动力学和临床活性。
J Mycol Med. 2018 Mar;28(1):15-22. doi: 10.1016/j.mycmed.2018.02.002. Epub 2018 Mar 16.
3
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.曲霉病的诊断和治疗：2017 年 ESCMID-ECMM-ERS 指南执行摘要。
Clin Microbiol Infect. 2018 May;24 Suppl 1:e1-e38. doi: 10.1016/j.cmi.2018.01.002. Epub 2018 Mar 12.
4
Isavuconazole: A new broad-spectrum azole. Part 1: In vitro activity.伊曲康唑：一种新型广谱唑类药物。第 1 部分：体外活性。
J Mycol Med. 2018 Mar;28(1):8-14. doi: 10.1016/j.mycmed.2018.02.005. Epub 2018 Mar 11.
5
Filter Adsorption of Anidulafungin to a Polysulfone-Based Hemofilter During CVVHD In Vitro.体外连续性静脉-静脉血液透析（CVVHD）期间阿尼芬净在聚砜基血液滤过器上的滤器吸附作用
Artif Organs. 2018 Feb;42(2):200-207. doi: 10.1111/aor.12982. Epub 2017 Oct 13.
6
ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients.ECIL-6白血病和造血干细胞移植患者侵袭性念珠菌病、曲霉病和毛霉病治疗指南。
Haematologica. 2017 Mar;102(3):433-444. doi: 10.3324/haematol.2016.152900. Epub 2016 Dec 23.
7
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.曲霉病诊断和管理实践指南：美国感染病学会2016年更新版
Clin Infect Dis. 2016 Aug 15;63(4):e1-e60. doi: 10.1093/cid/ciw326. Epub 2016 Jun 29.
8
Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints.艾沙康唑在实验性侵袭性肺曲霉病中的药效学：对临床断点的影响
J Antimicrob Chemother. 2016 Jul;71(7):1885-91. doi: 10.1093/jac/dkw098. Epub 2016 Apr 15.
9
EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents.EUCAST 关于曲霉属伏立康唑折点、念珠菌属伊曲康唑折点的技术说明，以及抗真菌药物敏感性检测方法文件的更新。
Clin Microbiol Infect. 2016 Jun;22(6):571.e1-4. doi: 10.1016/j.cmi.2016.01.017. Epub 2016 Feb 3.
10
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.伊曲康唑与伏立康唑治疗曲霉菌和其他丝状真菌所致侵袭性霉菌病的初步治疗（SECURE）：一项 3 期随机对照非劣效性试验。
Lancet. 2016 Feb 20;387(10020):760-9. doi: 10.1016/S0140-6736(15)01159-9. Epub 2015 Dec 10.